Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director · PRESIDENT AND CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 235,244 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 18,500 · Balance 253,744 Row 2 · 2026-09-15 · Sale · Disposed 18,500 · Balance 235,244 F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2030-12-15 | Direct | 488,801 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 18,500 · Balance 488,801 F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:28 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001859453-26-000015 · form4-09172026_080936.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 488,801 Underlying: Class A Common Stock · 18,500 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:28 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 18,500 | $37.00 | $684,500.00 |
DisclosureSEC source: 0001859453-26-000015 · form4-09172026_080936.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F1 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:28 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 18,500 | $2.90 | $53,590.80 |
DisclosureSEC source: 0001859453-26-000015 · form4-09172026_080936.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001859453-26-000014 · form4-09042026_040901.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 507,301 Underlying: Class A Common Stock · 18,500 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 18,500 | $35.12 | $649,642.30 |
DisclosureSEC source: 0001859453-26-000014 · form4-09042026_040901.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F1 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 18,500 | $2.90 | $53,590.80 |
DisclosureSEC source: 0001859453-26-000014 · form4-09042026_040901.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:45 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,200 | $43.59 | $95,908.34 |
DisclosureSEC source: 0001859453-26-000010 · form4-07092026_040701.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,994 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:45 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,500 | $42.86 | $450,006.90 |
DisclosureSEC source: 0001859453-26-000010 · form4-07092026_040701.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,194 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:45 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 32,550 | $42.07 | $1,369,495.68 |
DisclosureSEC source: 0001859453-26-000010 · form4-07092026_040701.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,694 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:45 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,000 | $40.78 | $40,776.20 |
DisclosureSEC source: 0001859453-26-000010 · form4-07092026_040701.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,244 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,250 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · derivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 525,801 Underlying: Class A Common Stock · 46,250 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,200 | $43.59 | $95,908.34 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,500 | $42.86 | $450,006.90 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,444 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 32,550 | $42.07 | $1,369,495.68 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,944 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,000 | $40.78 | $40,776.20 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,494 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| July 07, 2026 Filed Aug 12, 2026 22:42 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 46,250 | $2.90 | $133,977.00 |
DisclosureSEC source: 0001859453-26-000013 · form4a-08122026_100831.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:55 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 88 | $38.43 | $3,381.84 |
DisclosureSEC source: 0001859453-26-000008 · form4-06242026_080643.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,244 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:55 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 18,412 | $37.93 | $698,387.41 |
DisclosureSEC source: 0001859453-26-000008 · form4-06242026_080643.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,332 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Aug 12, 2026 22:41 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001859453-26-000012 · form4a-08122026_100823.xml · derivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 572,051 Underlying: Class A Common Stock · 18,500 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. Read SEC document |
| June 23, 2026 Filed Aug 12, 2026 22:41 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 88 | $38.43 | $3,381.84 |
DisclosureSEC source: 0001859453-26-000012 · form4a-08122026_100823.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| June 23, 2026 Filed Aug 12, 2026 22:41 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 18,412 | $37.93 | $698,387.41 |
DisclosureSEC source: 0001859453-26-000012 · form4a-08122026_100823.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,332 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| June 23, 2026 Filed Aug 12, 2026 22:41 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 18,500 | $2.90 | $53,590.80 |
DisclosureSEC source: 0001859453-26-000012 · form4a-08122026_100823.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:26 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 4,281 | $37.09 | $158,768.59 |
DisclosureSEC source: 0001859453-26-000007 · form4-05132026_080543.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,744 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed May 13, 2026 20:26 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,219 | $36.64 | $520,978.47 |
DisclosureSEC source: 0001859453-26-000007 · form4-05132026_080543.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,025 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2026 Filed Aug 12, 2026 22:39 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001859453-26-000011 · form4a-08122026_100809.xml · derivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590,551 Underlying: Class A Common Stock · 18,500 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. Read SEC document |
| May 12, 2026 Filed Aug 12, 2026 22:39 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 4,281 | $37.09 | $158,768.59 |
DisclosureSEC source: 0001859453-26-000011 · form4a-08122026_100809.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| May 12, 2026 Filed Aug 12, 2026 22:39 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,219 | $36.64 | $520,978.47 |
DisclosureSEC source: 0001859453-26-000011 · form4a-08122026_100809.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,525 F2 · kind: The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| May 12, 2026 Filed Aug 12, 2026 22:39 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 18,500 | $2.90 | $53,590.80 |
DisclosureSEC source: 0001859453-26-000011 · form4a-08122026_100809.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". F1 · balance_after: This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 "Amount of Securities Beneficially Owned Following Reported Transaction(s)". Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 900 | $45.51 | $40,960.26 |
DisclosureSEC source: 0001859453-26-000006 · form4-04152026_080434.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,244 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $45.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 7,921 | $44.58 | $353,105.51 |
DisclosureSEC source: 0001859453-26-000006 · form4-04152026_080434.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,144 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.20, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 14, 2026 Filed Apr 15, 2026 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 14,130 | $43.66 | $616,985.04 |
DisclosureSEC source: 0001859453-26-000006 · form4-04152026_080434.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,065 F1 · kind: This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.24, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,032 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2026. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 00:58 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 16,925 | $41.98 | $710,577.51 |
DisclosureSEC source: 0001859453-26-000004 · form4-02262026_120224.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,163 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2 · kind: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 01:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 137,500 | $0.00 Strike: $42.74 | $0.00 |
DisclosureSEC source: 0001859453-26-000002 · form4-02062026_080211.xml · derivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,500 Underlying: Class A Common Stock · 137,500 shares Expires 2036-02-03 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 01:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 68,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001859453-26-000002 · form4-02062026_080211.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,088 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 623 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,100 | $28.32 | $31,150.13 |
DisclosureSEC source: 0001415889-25-005841 · form4-02272025_090225.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,665 F5 · kind: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 7,975 | $27.55 | $219,731.99 |
DisclosureSEC source: 0001415889-25-005841 · form4-02272025_090225.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,765 F5 · kind: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 21, 2025 Filed Feb 27, 2025 21:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,613 | $27.89 | $296,031.59 |
DisclosureSEC source: 0001415889-25-005841 · form4-02272025_090225.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,740 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025. F2 · deemedExecutionDate: Pursuant to Rule 16a-3(g)(2) and (3). F3 · kind: Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 161,500 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001415889-25-004845 · form4-02202025_090218.xml · derivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,500 Underlying: Class A Common Stock · 161,500 shares Expires 2035-02-17 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 80,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004845 · form4-02202025_090218.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,353 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · derivative · entry 9 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 609,051 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,625 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · derivative · entry 8 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 610,926 Underlying: Class A Common Stock · 15,625 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,875 | $42.00 | $78,750.00 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 6 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,603 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,875 | $2.90 | $5,431.50 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 5 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,650 | $42.03 | $237,488.71 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 4 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,603 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.19, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,650 | $2.90 | $16,366.92 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 3 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 9,975 | $41.53 | $414,296.66 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 2 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,603 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.85, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 9,975 | $2.90 | $28,895.58 |
DisclosureSEC source: 0001415889-25-001242 · form4-01102025_090146.xml · nonDerivative · entry 1 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,661 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · derivative · entry 15 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 626,551 Underlying: Class A Common Stock · 57,661 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 57,661 | $2.90 | $167,032.38 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · nonDerivative · entry 11 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001415889-24-029964 · form4-12202024_091238.xml · derivative · entry 14 Fordyce Marshall · CIK 0001859453 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 684,212 Underlying: Class A Common Stock · 1,875 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.